CO6400198A2 - Composiciones y metodos novedosos - Google Patents

Composiciones y metodos novedosos

Info

Publication number
CO6400198A2
CO6400198A2 CO11009236A CO11009236A CO6400198A2 CO 6400198 A2 CO6400198 A2 CO 6400198A2 CO 11009236 A CO11009236 A CO 11009236A CO 11009236 A CO11009236 A CO 11009236A CO 6400198 A2 CO6400198 A2 CO 6400198A2
Authority
CO
Colombia
Prior art keywords
methods
new compositions
rv1753c
protein sequence
relates
Prior art date
Application number
CO11009236A
Other languages
English (en)
Spanish (es)
Inventor
James E Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO6400198A2 publication Critical patent/CO6400198A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
CO11009236A 2008-07-25 2011-01-27 Composiciones y metodos novedosos CO6400198A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8369208P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
CO6400198A2 true CO6400198A2 (es) 2012-03-15

Family

ID=41172233

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11009236A CO6400198A2 (es) 2008-07-25 2011-01-27 Composiciones y metodos novedosos

Country Status (24)

Country Link
US (2) US9315556B2 (US07981874-20110719-C00313.png)
EP (1) EP2315597B1 (US07981874-20110719-C00313.png)
JP (1) JP5824360B2 (US07981874-20110719-C00313.png)
KR (2) KR20110060891A (US07981874-20110719-C00313.png)
CN (2) CN102164612B (US07981874-20110719-C00313.png)
AU (1) AU2009273133B2 (US07981874-20110719-C00313.png)
BR (1) BRPI0916705A2 (US07981874-20110719-C00313.png)
CA (1) CA2731549C (US07981874-20110719-C00313.png)
CO (1) CO6400198A2 (US07981874-20110719-C00313.png)
CY (1) CY1119737T1 (US07981874-20110719-C00313.png)
EA (1) EA022203B1 (US07981874-20110719-C00313.png)
ES (1) ES2647321T3 (US07981874-20110719-C00313.png)
HR (1) HRP20171694T1 (US07981874-20110719-C00313.png)
HU (1) HUE037121T2 (US07981874-20110719-C00313.png)
IL (1) IL210588A0 (US07981874-20110719-C00313.png)
LT (1) LT2315597T (US07981874-20110719-C00313.png)
MX (1) MX2011000981A (US07981874-20110719-C00313.png)
NO (1) NO2315597T3 (US07981874-20110719-C00313.png)
PL (1) PL2315597T3 (US07981874-20110719-C00313.png)
PT (1) PT2315597T (US07981874-20110719-C00313.png)
SG (1) SG10201505149WA (US07981874-20110719-C00313.png)
SI (1) SI2315597T1 (US07981874-20110719-C00313.png)
UA (1) UA107180C2 (US07981874-20110719-C00313.png)
WO (1) WO2010010180A1 (US07981874-20110719-C00313.png)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106866801A (zh) 2008-07-25 2017-06-20 葛兰素史密丝克莱恩生物有限公司 结核病rv2386c蛋白、组合物及其用途
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
WO2020214961A1 (en) * 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Methods of treating tuberculosis
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016146A (en) * 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
DE69327599T2 (de) * 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
NZ507378A (en) 1998-04-07 2002-12-20 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU7383500A (en) 1999-09-17 2001-04-17 United States Government, As Represented By The Department Of Veteran's Affairs Virulence genes of m. marinum and m. tuberculosis
AU779978B2 (en) 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
WO2005076010A2 (en) * 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
KR20150036658A (ko) * 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EA021391B1 (ru) * 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
CN106866801A (zh) 2008-07-25 2017-06-20 葛兰素史密丝克莱恩生物有限公司 结核病rv2386c蛋白、组合物及其用途
CA2731499C (en) 2008-07-25 2017-01-10 Glaxosmithkline Biologicals S.A. Composition and use thereof for treating or preventing latent tuberculosis
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
TR201903223T4 (tr) 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген

Also Published As

Publication number Publication date
EP2315597A1 (en) 2011-05-04
AU2009273133B2 (en) 2014-06-05
CA2731549A1 (en) 2010-01-28
UA107180C2 (uk) 2014-12-10
CA2731549C (en) 2018-07-17
KR20110060891A (ko) 2011-06-08
US20160184420A1 (en) 2016-06-30
BRPI0916705A2 (pt) 2015-11-10
PL2315597T3 (pl) 2018-01-31
JP5824360B2 (ja) 2015-11-25
ES2647321T3 (es) 2017-12-20
CN108059660A (zh) 2018-05-22
US9750794B2 (en) 2017-09-05
CN102164612B (zh) 2018-01-16
KR20160013262A (ko) 2016-02-03
WO2010010180A1 (en) 2010-01-28
MX2011000981A (es) 2011-03-02
PT2315597T (pt) 2017-11-20
NO2315597T3 (US07981874-20110719-C00313.png) 2018-01-20
HRP20171694T1 (hr) 2017-12-15
CN102164612A (zh) 2011-08-24
CY1119737T1 (el) 2018-06-27
HUE037121T2 (hu) 2018-08-28
JP2011528897A (ja) 2011-12-01
LT2315597T (lt) 2018-02-12
SI2315597T1 (sl) 2017-12-29
US9315556B2 (en) 2016-04-19
US20110223200A1 (en) 2011-09-15
SG10201505149WA (en) 2015-07-30
AU2009273133A1 (en) 2010-01-28
EP2315597B1 (en) 2017-08-23
EA022203B1 (ru) 2015-11-30
IL210588A0 (en) 2011-03-31
EA201100071A1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
CO6400198A2 (es) Composiciones y metodos novedosos
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CL2020000428A1 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana.
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
BRPI0715396B8 (pt) método de produção de uma composição para vacina
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
GT200900163A (es) Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion.
CU20080133A7 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
EA201171494A1 (ru) Миметики белка smac
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
BR112014007675A2 (pt) tratamento de doença articular degenerativa
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
ECSP10010211A (es) Composición
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas

Legal Events

Date Code Title Description
FC Application refused